Antibodies to human N3pGlu Aá, compositions comprising such N3pGlu Aá antibodies, and methods of using such N3pGlu Aá antibodies for the treatment of a disease characterized by deposition of Aá including clinical or pre-clinical Alzheimers disease, Downs syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.